AKT1 and neoplasm: We suggest that AKT/TWIST/mTOR pathway should be targeted to affect (i) CSC survival, (ii) “bulk” tumor cells, and (iii) the non-CSC to CSC reversion phenotype (using additional CSC cell lines).